Alternative Tobacco Products for Current Smokers


PI: Dr. Tracy Smith

This trial investigates the impact of different e-cigarette device characteristics on reinforcement value, e-cigarette uptake, and downstream effects on cigarette smoking. Smokers (N=180) are recruited locally and will receive an e-cigarette and e-liquid for 3 weeks. The e-cigarette will either have a higher or lower device wattage, and the e-liquid will either have a higher or lower nicotine concentration. Participants sample the product in the lab and then take it home for 3 weeks to use as they wish. Participants return to the lab weekly to receive more e-liquids. There is no requirement to quit or change smoking.

E-Cigarette Study Eligibility Screening


PI: Dr. Tracy Smith

ESCAPE (Evaluating the Success of flavored e-Cigarettes for Achieving Prolonged smoking abstinencE) is co-led by Dr. Smith and Dr. Theodore Wagener at Ohio State University. ESCAPE is a NIDA and FDA-funded nationwide clinical trial which will investigate the impact of e-cigarette flavoring on switching from cigarettes to e-cigarettes among current cigarette smokers. People who currently smoke cigarettes (N=1500) will be recruited nationally and will receive 12 weeks of e-cigarettes or nicotine replacement therapy. Participants will try to switch completely to their assigned product and will complete regular remote data assessments.

Switch or Quit

PI: Dr. Tracy Smith

Switch or Quit investigates the potential for e-cigarettes to reduce the harms from tobacco among people who have tried to quit with FDA-approved pharmacotherapy and were unable to do so. People who currently smoke cigarettes (N=225) will be recruited statewide and receive either 9 weeks of e-cigarette product or 9 weeks of FDA approved medication. People who receive medication will choose between nicotine replacement therapy and varenicline. Participants will set a date on which they plan to stop smoking completely and use their assigned products instead. Participants will complete regular phone calls and daily diaries throughout the study. Come back later in 2023 for a link to the study screening survey.